MindMaze
the Swiss company, originally built around VR-based post-stroke neurorehabilitation, continued its European clinical expansion in 2026 by enrolling first patients in the SwissNeuroRehab high-dose, high-intensity neurorehabilitation study and launching the REACT-AVC study at Hospices Civils de Lyon;…
- Country
- Switzerland
clinical-rehab
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Consumer neurotech & wellness BCI / EEG | regenerative-personalized | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.